Beximco has bolstered its position in the US by bumping up its portfolio to 14 approved generics through a deal with Sandoz for a portfolio of eight ANDAs.
Beximco has more than doubled its portfolio in the US after striking a deal with Sandoz to buy a portfolio of eight undisclosed abbreviated new drug applications (ANDAs) from the Novartis subsidiary.
Currently, Beximco markets four products in the US through an alliance with local partner Bayshore. (Also see "Alliances, An...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
